ZICONOTIDE ACETATE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021060s006lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/15578997

Ziconotide (PRIALT; SNX-111) is a neuroactive peptide, which was approved by FDA in 2004 for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Ziconotide acts as a selective N-type voltage-gated calcium channel blocker, which leads to a blockade of excitatory neurotransmitter release from the primary afferent nerve terminals.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-dependent N-type calcium channels 2 Target ID: Voltage-dependent N-type calcium channels Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021060s006lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15578997	Blocker 555

Conditions

Condition	Modality	Targets	Highest Phase	Product
severe chronic pain 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021060s006lbl.pdf	Primary		Approved 8583	PRIALT Approved Use PRIALT (ziconotide) solution, intrathecal infusion is an N-type calcium channel antagonist indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Launch Date 2004

PubMed

Title	Date	PubMed
Pharmacological Inhibition of Voltage-gated Ca(2+) Channels for Chronic Pain Relief.	2013-12	24396337
Mechanisms of conotoxin inhibition of N-type (Ca(v)2.2) calcium channels.	2013-07	23380425
Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR.	2006-09-14	16844100
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.	2004-12	15578997
Identification and characterization of novel human Ca(v)2.2 (alpha 1B) calcium channel variants lacking the synaptic protein interaction site.	2002-01-01	11756491
Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes.	2000-11-10	10938268
Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus.	1998-11	9792182
Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom.	1987-04-21	2441741

Sample Use Guides

In Vivo Use Guide

PRIALT (ziconotide) solution is intended for administration by or under the direction of a physician experienced in the technique of intrathecal administration and who is familiar with the drug and device labeling. PRIALT may be used for therapy undiluted (25 mcg/mL in 20 mL vial) or diluted (100 mcg/mL in 1 or 5 mL vials). The 100 mcg/mL formulation may be administered undiluted once an appropriate dose has been established.

Route of Administration: Other

Name

Type

Language

ZICONOTIDE ACETATE

Common Name

English

PRIALT

Preferred Name

English

SNX-111 ACETATE

Code

English

ZICONOTIDE ACETATE [MART.]

Common Name

English

ZICONOTIDE ACETATE [ORANGE BOOK]

Common Name

English

Ziconotide Acetate [WHO-DD]

Common Name

English

.OMEGA.-CONOTOXIN M VIIA, ACETATE (SALT)

Common Name

English

.OMEGA.-CONOTOXIN M VIIA ACETATE

Common Name

English

CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2 ACETATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2198